Integrating radiotheranostics into national cancer planning to avoid widening cancer survival gaps: the case for equity-adjusted value
The Lancet Medical Imaging & Theranostics · 2026
DOI: 10.1016/j.lanmit.2026.100009 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Isabelle von Polenz und 2 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiotheranostics, which integrates molecular imaging with targeted radionuclide therapy, has progressed from proof of concept to clinical standard faster than most national cancer plans have kept pace with. Both the European Medicines Agency and US Food and Drug Administration approvals of 177Lu-DOTATATE for neuroendocrine tumours and 177Lu-prostate-specific membrane antigen-617 for metastatic castration-resistant prostate cancer have transformed disease management, and the pipeline of radioligand therapy trials continues to expand to other targets and diseases.
Zitieren
APA
Polenz, I. V., Giammarile, F., & Mansi, L. (2026). Integrating radiotheranostics into national cancer planning to avoid widening cancer survival gaps: the case for equity-adjusted value. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100009
Vancouver
Polenz IV, Giammarile F, Mansi L. Integrating radiotheranostics into national cancer planning to avoid widening cancer survival gaps: the case for equity-adjusted value. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100009
BibTeX
@article{Polenz2026,
author = {Polenz, Isabelle von and Giammarile, Francesco and Mansi, Luigi},
title = {Integrating radiotheranostics into national cancer planning to avoid widening cancer survival gaps: the case for equity-adjusted value},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
doi = {10.1016/j.lanmit.2026.100009}
}
EUVIMED